These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11497396)

  • 21. A European phase II study of recombinant human granulocyte colony-stimulating factor (lenograstim) in the treatment of severe chronic neutropenia in children. Lenograstim Study Group.
    Donadieu J; Boutard P; Bernatowska E; Tchernia G; Couillaud G; Philippe N; Le Gall E
    Eur J Pediatr; 1997 Sep; 156(9):693-700. PubMed ID: 9296532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, crossover comparison of standard-dose versus low-dose lenograstim in the prophylaxis of post-chemotherapy neutropenia.
    Juan O; Campos JM; Carañana V; Sanchez JJ; Casañ R; Alberola V
    Support Care Cancer; 2001 Jun; 9(4):241-6. PubMed ID: 11430419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia.
    Bradstock K; Matthews J; Young G; Lowenthal R; Baxter H; Arthur C; Bashford J; Brighton T; Cannell P; Dunlop L; Durrant S; Enno A; Eliadis P; Gill D; Gillett A; Gottlieb D; Januszewicz H; Joshua D; Leahy M; Schwarer A; Taylor K;
    Leukemia; 2001 Sep; 15(9):1331-8. PubMed ID: 11516093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301.
    Takenaka T; Itoh K; Suzuki T; Utsunomiya A; Matsuda S; Chou T; Sai T; Sano M; Konda S; Ohno T; Mikuni C; Deura K; Yamada T; Mizorogi F; Nagoshi H; Tomonaga M; Hotta T; Kawano K; Tsushita K; Hirano M; Shimoyama M;
    Int J Hematol; 2004 Feb; 79(2):165-73. PubMed ID: 15005346
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
    Woll PJ; Hodgetts J; Lomax L; Bildet F; Cour-Chabernaud V; Thatcher N
    J Clin Oncol; 1995 Mar; 13(3):652-9. PubMed ID: 7533825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Which one is more effective, filgrastim or lenograstim, during febrile neutropenia attack in hospitalized patients with solid tumors?
    Sonmez OU; Guclu E; Uyeturk U; Esbah O; Turker I; Bal O; Budakoglu B; Arslan UY; Karabay O; Oksuzoglu B
    Asian Pac J Cancer Prev; 2015; 16(3):1185-9. PubMed ID: 25735353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation.
    Gisselbrecht C; Prentice HG; Bacigalupo A; Biron P; Milpied N; Rubie H; Cunningham D; Legros M; Pico JL; Linch DC
    Lancet; 1994 Mar; 343(8899):696-700. PubMed ID: 7510813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings.
    Dunn CJ; Goa KL
    Drugs; 2000 Mar; 59(3):681-717. PubMed ID: 10776839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Granulocyte colony-stimulating factor in the combination chemotherapy for adult T-cell leukemia (ATL).
    Uozumi K; Nakahara K; Takatsuka Y; Ohno N; Makino T; Utsunomiya A; Hanada S; Arima T
    Leuk Lymphoma; 1998 Apr; 29(3-4):407-14. PubMed ID: 9684938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I-II trial of intensification of the MAID regimen with support of lenograstim (rHuG-CSF) in patients with advanced soft-tissue sarcoma (STS).
    Chevreau C; Bui BN; Chevallier B; Krakowski I; Maugard C; Mihura J; Coindre JM; Gil B; Cour-Chabernaud V
    Am J Clin Oncol; 1999 Jun; 22(3):267-72. PubMed ID: 10362334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
    Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study.
    Gatzemeier U; Kleisbauer JP; Drings P; Kaukel E; Samaras N; Melo MJ; Cardenal F; Robinet G; Snijder RJ; von Pawel J; Palisses R
    Am J Clin Oncol; 2000 Aug; 23(4):393-400. PubMed ID: 10955871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party.
    Wheatley K; Goldstone AH; Littlewood T; Hunter A; Burnett AK
    Br J Haematol; 2009 Jun; 146(1):54-63. PubMed ID: 19438472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer.
    Takada M; Fukuoka M; Ariyoshi Y; Furuse K; Niitani H; Ota K; Motomiya M; Hasegawa K; Tominaga K; Kuriyama T
    Cancer Chemother Pharmacol; 1992; 31(3):182-6. PubMed ID: 1281446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
    Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose granulocyte colony-stimulating factor overcomes neutropenia in the treatment of non-Hodgkin's lymphoma with higher cost-effectiveness.
    Hara T; Tsurumi H; Kasahara S; Kanemura N; Yoshikawa T; Goto N; Kojima Y; Yamada T; Sawada M; Takahashi T; Oyama M; Tomita E; Moriwaki H
    Int J Hematol; 2005 Dec; 82(5):430-6. PubMed ID: 16533747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma.
    Takeyama K; Ogura M; Morishima Y; Kasai M; Kiyama Y; Ohnishi K; Mitsuya H; Kawano F; Masaki Y; Sasaki T; Chou T; Yokozawa T; Tobinai K;
    Jpn J Clin Oncol; 2003 Feb; 33(2):78-85. PubMed ID: 12629058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
    Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
    N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
    Bhana N
    Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results.
    Palumbo A; Falco P; Falcone A; Benevolo G; Canepa L; Gay F; Larocca A; Magarotto V; Gozzetti A; Luraschi A; Morabito F; Nozza A; Knight RD; Zeldis JB; Boccadoro M; Petrucci MT
    Clin Lymphoma Myeloma; 2009 Apr; 9(2):145-50. PubMed ID: 19406725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.